ADAR1 Capital Management »

Evotec shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Evotec (EVO) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Evotec

Tip: Access up to 7 years of quarterly data

All positions including Evotec held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evotec by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $60k 7.7k 7.83

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Evotec

Mubadala Investment Co PJSC
Morgan Stanley
Millennium Management
DCF Advisers
Optiver Holding B.V.
BlackRock
Cetera Investment Advisers
ADAR1 Capital Management
Quadrant Capital
Bank of America Corporation
Briaud Financial Planning
UBS Group
Signature
Qube Research & Technologies
Us Bancorp

View all funds holding Evotec